Below please find a table outlining a discounted cash flow forecast for CYAN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Cyanotech Corp ranked in the 94th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 3678.83%. The most interesting components of our discounted cash flow analysis for Cyanotech Corp ended up being:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 57. Its equity weight surpasses that of only 23.56% of free cash flow generating stocks in the Consumer Defensive sector.
The company's compound free cash flow growth rate over the past 4.01 years comes in at 1.01%; that's greater than 90.3% of US stocks we're applying DCF forecasting to.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Consumer Defensive that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CYAN, try BIG, NATR, LOPE, TANH, and COKE.
Cyanotech® Corporation, (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announced that Charles (C.J.) Hartmann has joined Cyanotech as the company’s new Senior Sales and Marketing Director effective July 20, 2020. He fills a new position that the company deemed necessary in order to continue fueling growth and provide seasoned guidance.
Not all supplements are produced the same way. Today’s supplement market is growing with manufacturers rushing to get in on a business that a few companies have been building for decades. Marketing and packaging have allowed well-capitalized companies to create the illusion of quality and credibility without the experience nor the farmers and scientists that create our consistently high standards of quality.